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1. INTRODUCTION {#cam42912-sec-0005}
===============

Multiple prospective randomized trials[1](#cam42912-bib-0001){ref-type="ref"}, [2](#cam42912-bib-0002){ref-type="ref"}, [3](#cam42912-bib-0003){ref-type="ref"} have demonstrated no differences in overall survival (OS) or improved disease free survival (DFS) in patients receiving neoadjuvant chemotherapy (NAC) vs adjuvant chemotherapy (AC) for the treatment of breast cancer. NAC is being used more commonly, especially in cases of triple negative disease and human epidermal growth factor receptor 2 (HER2) positive disease[4](#cam42912-bib-0004){ref-type="ref"}, [5](#cam42912-bib-0005){ref-type="ref"} due to the dramatic clinical and pathologic responses often seen. Pathologic complete response rates for triple negative disease range from 23.2% to 33.6%, and for HER2 positive, hormone‐receptor negative disease from 38.7% to 66.2%.[6](#cam42912-bib-0006){ref-type="ref"}, [7](#cam42912-bib-0007){ref-type="ref"}

NAC is also appropriate for many breast cancer patients with large primary tumors who desire breast conservation,[1](#cam42912-bib-0001){ref-type="ref"}, [8](#cam42912-bib-0008){ref-type="ref"}, [9](#cam42912-bib-0009){ref-type="ref"} and its use may also downstage the axilla before nodal evaluation.[1](#cam42912-bib-0001){ref-type="ref"}, [8](#cam42912-bib-0008){ref-type="ref"}, [10](#cam42912-bib-0010){ref-type="ref"} It can also be used with the goal of eliminating systemic micrometastatic disease,[11](#cam42912-bib-0011){ref-type="ref"} and to safely delay surgery in certain situations; for example, by allowing time to medically optimize a patient prior to surgery or providing an opportunity to have genetic testing performed.[9](#cam42912-bib-0009){ref-type="ref"}

Additionally, times to treatment have become important, and longer times to surgery, chemotherapy, and radiotherapy all confer modest but significant impairments in survival.[12](#cam42912-bib-0012){ref-type="ref"} While we were unable to find evidence in the published medical literature, it is thought by some that NAC is typically initiated more quickly than proceeding directly to surgery. Despite this view, there is no data available, to our knowledge, regarding the time it takes patients undergoing NAC to start chemotherapy, as vs the time it takes patients to have surgery first. This study was therefore performed to evaluate the times to start and complete breast cancer treatment in each of these settings to assess whether rapidity of treatment is a benefit of NAC.

2. MATERIALS AND METHODS {#cam42912-sec-0006}
========================

Data were obtained from the National Cancer Database (NCDB). Women ≥18 years old with newly diagnosed, nonrecurrent, noninflammatory, clinical stage I‐III breast cancer diagnosed between 2004 and 2015 whose treatment included both surgery and chemotherapy were selected. Patients with recurrent disease, multiple tumors and/or inflammatory breast cancer were also excluded due to their bad prognosis and varied treatment paradigms, and patients in whom a biopsy was not documented in the dataset were excluded. Remaining exclusions are elaborated in Figure [1](#cam42912-fig-0001){ref-type="fig"}.

![Exclusion diagram](CAM4-9-2742-g001){#cam42912-fig-0001}

Patients were then divided into two groups; those who received NAC and those who received AC. They were then further stratified based on whether they also received radiotherapy and endocrine therapy (Figure [2](#cam42912-fig-0002){ref-type="fig"}). Treatment times were measured from time of biopsy to start of first treatment (with first treatment being chemotherapy for NAC group, and surgery for AC group). Time from biopsy to the start of radiotherapy was also measured for all patients who received radiation. Time from biopsy to the start of endocrine therapy was also analyzed. The start of endocrine therapy was used as a surrogate for the end of treatment. Thus, only patients who received endocrine therapy (n = 52 264) were included in that portion of the analysis.

![Characterization of patients based on treatment sequence. Patients were initially divided into 2 categories, based on whether they were treated with neoadjuvant chemotherapy or adjuvant chemotherapy. Within those groups, they were then further characterized into 3 groups: Those treated with only surgery and chemotherapy, those who also had radiation, and those who also had radiation and endocrine therapy. These individual groups represent the cohorts included in this study. Times to start treatment (time from biopsy to surgery, or from biopsy to chemotherapy) included all groups. Times to radiation included only those having that modality. Times to complete treatment were measured in those having endocrine therapy. Abbreviations: AC, Adjuvant chemotheraphy; B, Time of biopsy; C, Chemotherapy; E, Endocrine theraphy; NAC, Neoadjuvant chemotheraphy; R, Radiotheraphy; S, Surgery.](CAM4-9-2742-g002){#cam42912-fig-0002}

Comparisons between the groups were performed using Student\'s *t* test for continuous variables and chi‐squared test for categorical variables. To minimize the potential selection bias, treatment times were adjusted for facility volume, age, race, education, insurance, income, setting (urban vs rural vs metropolitan), facility distance, treatment at more than one facility, Charlson comorbidity index, histology, grade, clinical T stage, clinical N stage, AJCC clinical stage, pathologic T stage, pathologic N stage, and phenotype (estrogen, progesterone and HER2) by propensity score with 1:1 matching method. Multiple regression models with log‐transformed treatment times (due to skewed distribution) and with length of hospital stay (approximately normal distribution), as well as multivariable logistic regression models with readmission and 30‐ and 90‐day mortality were constructed to determine predictors associated with these clinical outcomes.

All analyses were performed using SAS 9.4 (SAS Inc). Statistical tests were two‐sided, and a *P*‐value of \<.05 was considered statistically significant.

3. RESULTS {#cam42912-sec-0007}
==========

3.1. Patient demographics & tumor characteristics {#cam42912-sec-0008}
-------------------------------------------------

After accounting for exclusion criteria, 155 606 women remained. Mean patient age was 54.4 ± 11.3 years. Most patients were white (74.8%). Of these, 28 241 patients received NAC and 127 365 patients received AC. Notably, patients treated with NAC tended to be younger (51.9 ± 11.6 years vs 54.9 ± 11.1 years, *P* \< .0001). On presentation, they also had larger tumors (cT3‐cT4: 35.8% vs 4.9%, *P* \< .0001) and greater nodal involvement (cN2‐cN3: 14.4% vs 3.7%, *P* \< .0001) as compared with those having AC. Most patients had ductal histology (86.47%) and the most common tumor phenotype was hormone receptor positive and HER2 negative (55.98%) (Table [1](#cam42912-tbl-0001){ref-type="table"}).

###### 

Cohort characteristics

                                      Overall (N = 155, 606)   NAC (N = 28 241)   AC (N = 127 365)   *P*                             
  ----------------------------------- ------------------------ ------------------ ------------------ ------- --------------- ------- ---------
  Facility characteristics                                                                                                           
  Facility volume                                                                                                                    
  Low (0‐50 cases/y)                  117 716                  75.65              20 908             74.03   96 808          76.01   \<.0001
  Mid (51‐100 cases/y)                28 945                   18.60              5988               21.20   22 957          18.02    
  High (\>100 cases/y)                8945                     5.75               1345               4.76    7600            5.97     
  Patient characteristics                                                                                                            
  Age, mean ± SD                      54.36 ± 11.28                               51.93 ± 11.58              54.90 ± 11.14           \<.0001
  Race                                                                                                                               
  Caucasian                           116 400                  74.80              18 821             66.64   97 579          76.61   \<.0001
  African American                    21 398                   13.75              5319               18.83   16 079          12.62    
  Hispanic                            9671                     6.22               2448               8.67    7223            5.67     
  Asian‐Pacific Islander              5688                     3.66               1141               4.04    4547            3.57     
  Other/unknown                       2449                     1.57               512                1.81    1937            1.52     
  Education                                                                                                                          
  21% or more                         23 558                   15.20              5141               18.29   18 417          14.51   \<.0001
  13%‐20.9%                           37 575                   24.20              7146               25.43   30 369          23.93    
  7%‐12.9%                            50 883                   32.83              8856               31.51   42 027          33.12    
  \<7%                                43 042                   27.77              6960               24.77   36 082          28.43    
  Insurance                                                                                                                          
  Not Insured                         4530                     2.91               1405               4.98    3125            2.45    \<.0001
  Private insurance                   102 627                  65.95              17 907             63.41   84 720          66.52    
  Medicaid                            13 916                   8.94               3760               13.31   10 156          7.97     
  Medicare                            31 102                   19.99              4472               15.84   26 630          20.91    
  Other Government                    1751                     1.13               324                1.15    1427            1.12     
  Unknown                             1680                     1.08               373                1.32    1307            1.03     
  Income                                                                                                                             
  Less than \$38 000                  24 203                   15.62              4984               17.74   19 219          15.15   \<.0001
  \$38 000‐\$47 999                   33 145                   21.39              6141               21.86   27 004          21.29    
  \$48 000‐\$62 999                   41 486                   26.77              7536               26.82   33 950          26.76    
  \$63 000+                           56 112                   36.21              9436               33.58   46 676          36.80    
  Urban/rural                                                                                                                        
  Metro                               130 651                  86.11              24 127             87.73   106 524         85.75   \<.0001
  Urban                               18 708                   12.33              3017               10.97   15 691          12.63    
  Rural                               2372                     1.56               356                1.29    2016            1.62     
  Facility distance (miles)                                                                                                          
  \<25                                127 811                  82.47              22 897             81.51   104 914         82.69   \<.0001
  25‐50                               17 061                   11.01              3034               10.80   14 027          11.06    
  50‐75                               4793                     3.09               927                3.30    3866            3.05     
  \>75                                5306                     3.42               1232               4.39    4074            3.21     
  Treated at more than one facility                                                                                                  
  No                                  123 765                  79.54              21 834             77.31   101 931         80.03   \<.0001
  Yes                                 31 841                   20.46              6407               22.69   25 434          19.97    
  Charlson Comorbidity Index                                                                                                         
  0                                   133 123                  85.55              24 852             88.00   108 271         85.01   \<.0001
  1                                   19 001                   12.21              2885               10.22   16 116          12.65    
  2                                   2847                     1.83               403                1.43    2444            1.92     
  3                                   635                      0.41               101                0.36    534             0.42     
  Tumor characteristics                                                                                                              
  Histology                                                                                                                          
  Ductal                              134 553                  86.47              24 627             87.20   109 926         86.31   \<.0001
  Lobular                             11 062                   7.11               1772               6.27    9290            7.29     
  Other/unknown                       9991                     6.42               1842               6.52    8149            6.40     
  Grade                                                                                                                              
  Grade 1                             12 672                   8.14               1564               5.54    11 308          8.72    \<.0001
  Grade 2                             55 677                   35.78              9121               32.30   46 556          36.55    
  Grade 3 & anaplastic                80 522                   51.75              15 539             55.02   64 983          51.02    
  Unknown                             6735                     4.33               2017               7.14    4718            3.70     
  Clinical T stage                                                                                                                   
  0                                   122                      0.08               40                 0.14    82              0.06    \<.0001
  1                                   73 290                   47.10              3926               13.90   69 364          54.46    
  2                                   63 701                   40.94              13 839             49.00   49 862          39.15    
  3                                   12 797                   8.22               7251               25.68   5546            4.35     
  4                                   3574                     2.30               2869               10.16   705             0.55     
  Other/unknown                       2122                     1.36               316                1.12    1806            1.42     
  Clinical N stage                                                                                                                   
  0                                   111 546                  71.68              11 475             40.63   100 071         78.57   \<.0001
  1                                   30 930                   19.88              12 041             42.64   18 889          14.83    
  2                                   6044                     3.88               2689               9.52    3355            2.63     
  3                                   2737                     1.76               1363               4.83    1374            1.08     
  Other/unknown                       4349                     2.79               673                2.38    3676            2.89     
  AJCC clinical stage                                                                                                                
  I                                   64 258                   41.30              2106               7.46    62 152          48.80   \<.0001
  II                                  74 083                   47.61              16 268             57.61   57 815          45.39    
  III                                 17 263                   11.09              9866               34.94   7397            5.81     
  Pathologic T stage                                                                                                                 
  0                                   1345                     0.86               1292               4.57    53              0.04    \<.0001
  1                                   65 876                   42.34              11 604             41.09   54 272          42.61    
  2                                   57 623                   37.03              8040               28.47   49 583          38.93    
  3                                   9965                     6.40               3057               10.82   6908            5.42     
  4                                   1786                     1.15               997                3.53    789             0.62     
  Other/unknown                       19 011                   12.22              3251               11.51   15 760          12.37    
  Pathologic N stage                                                                                                                 
  0                                   69 078                   46.14              11 463             41.93   57 615          47.08   \<.0001
  1                                   40 437                   27.01              7457               27.28   32 980          26.95    
  2                                   14 399                   9.62               3724               13.62   10 675          8.72     
  3                                   6742                     4.50               1694               6.20    5048            4.12     
  Other/unknown                       19 068                   12.74              3000               10.97   16 068          13.13    
  Molecular marker status                                                                                                            
  HER2+, HR+                          11 676                   11.20              2149               10.96   9527            11.25   \<.0001
  HER2+, HR−                          7948                     7.62               1927               9.82    6021            7.11     
  HER2−, HR+                          58 377                   55.98              9185               46.83   49 192          58.10    
  HER2−, HR−                          26 274                   25.20              6353               32.39   19 921          23.53    
  Regional lymph node status                                                                                                         
  Negative                            78 037                   52.97              12 230             47.55   65 807          54.11   \<.0001
  Positive                            69 290                   47.03              13 489             52.45   55 801          45.89    

Abbreviations: AC, adjuvant chemotherapy; AJCC, American Joint Committee on Cancer; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NAC, neoadjuvant chemotherapy.

John Wiley & Sons, Ltd

3.2. Times to treatment {#cam42912-sec-0009}
-----------------------

Unadjusted time comparisons were first determined (Table [2](#cam42912-tbl-0002){ref-type="table"}). Time from biopsy to first treatment was 35.6 ± 27.5 days in patients treated with NAC, vs 33.4 ± 22.9 days in patients treated with AC (*P* \< .0001). Unadjusted time from biopsy to radiation was 243.2 ± 58.8 days in NAC vs 208.7 ± 54.6 days in AC (*P* \< .0001), and unadjusted time from biopsy to start of endocrine therapy was 305.4 ± 77.6 days in NAC vs 268.3 ± 71.1 days in AC (*P* \< .0001). After propensity score matching, adjusted times are detailed in Table [2](#cam42912-tbl-0002){ref-type="table"}. NAC patients had a similar time to begin treatment compared to AC patients, but took significantly longer to start radiotherapy and endocrine therapy.

###### 

Unmatched and propensity score‐matched time comparisons

                                NAC mean (d)   AC mean (d)    *P*‐value   Δ
  ----------------------------- -------------- -------------- ----------- ------
  Unmatched                                                               
  Biopsy to first treatment     35.6 ± 27.5    33.4 ± 22.9    \<.0001     2.2
  Biopsy to radiation           243.2 ± 58.8   208.7 ± 54.6   \<.0001     34.5
  Biopsy to endocrine therapy   305.4 ± 77.6   268.3 ± 71.1   \<.0001     37.1
  Matched                                                                 
  Biopsy to first treatment     36.1 ± 30.8    35.4 ± 25.7    .15         0.7
  Biopsy to radiation           240.8 ± 59.2   218.2 ± 56.6   \<.0001     22.6
  Biopsy to endocrine therapy   301.6 ± 70.4   275.7 ± 66.5   \<.0001     25.9

Abbreviations: AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy.

John Wiley & Sons, Ltd

3.3. Factors that influence treatment times {#cam42912-sec-0010}
-------------------------------------------

As depicted in Figure [3](#cam42912-fig-0003){ref-type="fig"}, predictors of times to treatment initiation were examined. The factors associated with a longer time to treatment initiation included higher volume facilities, black and Hispanic patients, increased income, and increased Charlson comorbidity index. Patients treated at more than one facility, along with black and Hispanic patients were more likely to have longer times to treatment initiation as well as delays in starting radiation and endocrine therapy. Factors associated with shorter times to first treatment, radiation therapy, and endocrine therapy included higher education level, private insurance, and treatment in an urban or rural setting (as opposed to a metropolitan setting).

![Forest plots demonstrating factors that influence treatment times](CAM4-9-2742-g003){#cam42912-fig-0003}

3.4. Outcomes {#cam42912-sec-0011}
-------------

After propensity score matching, there was no difference in the length of hospital stay among patients treated with NAC vs AC (1.16 ± 4.93 vs 1.28 ± 5.90 days, *P* = .14). Rates of unplanned readmission were slightly lower in patients treated with NAC vs AC (1.18% vs 1.72%), however this was not clinically significant. Similarly, 30‐day mortality rates (0.04% vs 0.01%) and 90‐day mortality rates (0.30% vs 0.08%) were also not clinically different since the rates were so low.

3.5. Independent predictors of increased length of hospital stay, readmission & mortality {#cam42912-sec-0012}
-----------------------------------------------------------------------------------------

Multivariable analyses were performed to determine independent predictors of increased length of hospital stay, readmission, and 30‐ and 90‐day mortality rates. Predictors of increased length of hospital stay were Charlson comorbidity score of 3 (0.36 days longer, 95% confidence interval \[CI\] 0.01‐1.19, *P* = .04), Charlson comorbidity score of 2 (0.26 days longer, 95% CI 0.06‐0.66, *P* \< .05), higher income (0.15 days longer, 95% CI 0.04‐0.37, *P* \< .05), black race (0.13 days longer, 95% CI 0.05‐0.29, *P* \< .0001) and Hispanic ethnicity (0.11 days longer, 95% CI 0.20‐0.30, *P* = .01). Charlson comorbidity score of 2 (odds ratio \[OR\] 2.3, 95% CI 1.52‐3.33, *P*=\<0.0001) was found to be the only predictor of increased readmission rates. Predictors of increased 30‐day mortality included Charlson comorbidity score of 3 (OR 15.46, 95% CI 1.55‐153.79, *P* = .02), patients with HER2 positive, hormone receptor negative disease (OR 6.75, 95% CI 1.05‐43.37, *P* = .04), higher income (OR 6.29, 95% CI 1.15‐34.49, *P* = .03), and black race (OR 3.70, 95% CI 1.40‐9.78, *P*=.01). Predictors of increased 90‐day mortality included Charlson comorbidity score of 2 (OR 3.18, 95% CI 1.15‐8.83, *P* = .03), higher income (OR 3.08, 95% CI 1.06‐8.95, *P* = .04), facility distance of 25‐50 miles (OR 2.5, 95% CI 1.17‐5.37, *P* = .02), black race (OR 1.89, 95% CI 1.01‐3.53, *P* = .05), and older age (1.06, 95% CI 1.03‐3.53, *P* = .05) (Table [3](#cam42912-tbl-0003){ref-type="table"}).

###### 

Independent predictors of increased length of stay, readmission & mortality

                                  Increased length of stay   Increased readmission   Increased 30‐d mortality   Increased 90‐d mortality
  ------------------------------- -------------------------- ----------------------- -------------------------- --------------------------
  Black race                      **√**                                              **√**                      **√**
  Hispanic ethnicity              **√**                                                                          
  Older age                                                                                                     **√**
  Higher income                                                                      **√**                      **√**
  Charlson comorbidity score 2    **√**                      **√**                                               
  Charlson comorbidity score 3    **√**                                              **√**                       
  Facility distance 25‐50 miles                                                                                 **√**
  HER2+, HR− disease                                                                 **√**                       

Factors that were also evaluated but were not significant were education level, clinical nodal status, tumor histology (ductal vs lobular), HER2−/HR+ tumors and triple negative tumors.

Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42912-sec-0013}
=============

NAC has benefits in the management of breast cancer including shrinking the size of the primary tumor to allow for increased rates of breast conservation, and downstaging disease in the axilla. Some proponents of NAC also believe that it shortens the time to treatment initiation compared to upfront surgery, however, to our knowledge, there is no data substantiating this claim, even though the published medical literature does provide data relating to general delays in breast cancer care.[13](#cam42912-bib-0013){ref-type="ref"}, [14](#cam42912-bib-0014){ref-type="ref"}

The interest in whether NAC improves time to treatment initiation likely originates from data showing that a longer time to surgery is associated with lower OS and DFS in breast cancer patients, with the largest decline seen in patients having stage I and II disease.[13](#cam42912-bib-0013){ref-type="ref"} While delays to surgery are significant, a delay of \>90 days as vs ≤30 days has been found to be associated with only a 3%‐5% decrement in survival.[13](#cam42912-bib-0013){ref-type="ref"} Similarly, a delay of more than 90 days to initiation of chemotherapy is also associated with worse OS and breast cancer‐specific survival,[15](#cam42912-bib-0015){ref-type="ref"}, [16](#cam42912-bib-0016){ref-type="ref"} and a study evaluating patients with hormone receptor‐negative breast cancer found that delaying chemotherapy by 6 weeks resulted in worse OS.[17](#cam42912-bib-0017){ref-type="ref"} Regarding delays to initiation of adjuvant radiotherapy, the data is mixed, with some studies suggesting that outcomes are unaffected when radiation is given between 8 and 20 weeks postoperatively in patients who do not receive chemotherapy, and within 365 days in patients who do receive chemotherapy.[12](#cam42912-bib-0012){ref-type="ref"}

For these reasons, quality measures currently specify three recommended time intervals[18](#cam42912-bib-0018){ref-type="ref"}: firstly, that radiotherapy should be given within 365 days of diagnosis in women under the age of 70 who have breast conserving surgery. Secondly, that chemotherapy should be considered or administered within 4 months of diagnosis for women under the age of 70 with AJCC T1c, Stage II, or Stage III hormone‐receptor‐negative breast cancer, and thirdly, that tamoxifen or a third‐generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with AJCC T1c, Stage II, or Stage III hormone receptor positive breast cancer. Compliance with these measures is tracked by accrediting bodies such as the National Accreditation Program for Breast Centers[18](#cam42912-bib-0018){ref-type="ref"} because of the importance of appropriately initiating treatment without undue delay. Avoiding treatment delays is therefore important to both optimize outcomes and comply with quality measures.

After adjusting for numerous factors, we found that time from biopsy to treatment initiation (either surgery or chemotherapy) was similar in patients receiving NAC vs AC. Thus, NAC does not expedite time to treatment initiation, even though there may be situations where NAC may be desirable if undue preoperative delays are unavoidable.

Delays to surgery also have an impact on time to chemotherapy and this could affect compliance with the chemotherapy quality measure. Patients who undergo mastectomy with or without reconstruction are at a higher risk of having delays to AC due to longer recovery time and higher rate of postoperative complications.[19](#cam42912-bib-0019){ref-type="ref"} For patients undergoing larger procedures where postoperative recovery time is predicted to be unusually prolonged, it may be reasonable to treat them with chemotherapy upfront.

It must be remembered that times to treatment are likely eclipsed by the "silent interval" of a tumor, which is defined as the period of tumor growth beginning at inception, up until it can be detected. By definition, we cannot know the length of this period of time, but it is generally thought that these intervals frequently comprise the majority of a tumor\'s lifespan.[20](#cam42912-bib-0020){ref-type="ref"} It is because of this that delays to surgery, chemotherapy or radiotherapy likely have much less of an impact than typically surmised.

We found that the time to initiation of radiotherapy was 3.2 weeks longer in the NAC group than in the AC group, however, this delay of 3 weeks in the NAC cohort is unlikely to impact clinical outcomes in most cases. Most published studies have found that delays in radiotherapy of at least 8‐20 weeks are required before a decline in survival or an increase in local recurrence is seen.[12](#cam42912-bib-0012){ref-type="ref"} However, a study evaluating 581 patients specifically treated with NAC and postoperative radiotherapy found that initiating radiation \<8 weeks after surgery was associated with improved disease‐specific and OS.[21](#cam42912-bib-0021){ref-type="ref"} Ultimately, with multidisciplinary treatment, the impact of longer radiotherapy after changing the order of surgery and chemotherapy remains uncertain. However, the current radiotherapy standard requires that radiation be administered within 1 year of diagnosis,[18](#cam42912-bib-0018){ref-type="ref"} and so clinicians must, at minimum be cognizant of the fact that a 3‐week delay can mean the difference between compliance and noncompliance in terms of quality measures.

A second objective of our study was to assess the time to completion of treatment, and the start of endocrine therapy was used as a surrogate for this time point. Since endocrine therapy is given as an outpatient medication, compliance is difficult to monitor, and lengths of therapy can vary from 5 to 10 years, the start, rather than the completion, of hormonal therapy was felt to be a reliable estimate of the completion of their overall treatment course. Moreover, we are not aware of any similarly sized dataset that assesses either time to completion of endocrine therapy or the level of compliance. We found that time to completion of treatment was 3.7 weeks longer in the NAC group compared to the AC group. Unfortunately, there is no good data, to our knowledge, regarding delays in endocrine therapy on outcomes. Especially with time spans for hormonal therapy on treatment being 5‐10 years, delays over a matter of weeks likely make little difference. Moreover it must be remembered that the expansion of endocrine therapy from 5 to 10 years was to solely provide a 3% survival benefit,[22](#cam42912-bib-0022){ref-type="ref"} making any delays seen here likely inconsequential. We therefore do not suggest that the time delay to endocrine therapy, which is our surrogate for completion of treatment, in the NAC group has impaired survival, but instead simply that these data demonstrate that it has not expedited or improved outcomes related to potential delays.

In an effort to provide a potential explanation for differences between the NAC group and those having surgery first, we speculated that NAC might increase the risk of perioperative complications, resulting in increased length of hospital stay after surgery due to wound complications or other chemotherapy‐related side effects. However our analysis showed no difference in length of hospital stay between AC and NAC. This is consistent with prior studies that have found that NAC is not associated with an increase in short‐term complications after mastectomy and implant‐based reconstruction[23](#cam42912-bib-0023){ref-type="ref"} or autologous tissue reconstruction.[24](#cam42912-bib-0024){ref-type="ref"}

Similarly, we also examined whether the longer time to complete treatment in the NAC group was due to higher readmission rates, but surprisingly, patients treated with NAC actually had lower rates of both unplanned and planned readmission. The reason for this is unclear, but perhaps this could be due to the closer follow up and monitoring of these patients while they were undergoing chemotherapy. With regard to mortality rates, as expected, 30‐ and 90‐day mortality rates were very low and clinically insignificant. We therefore cannot attribute the longer time to completion of treatment to an increase in perioperative complications resulting from NAC. The small differences in timing are therefore more likely due to scheduling factors or even due to a self‐imposed delay to wait for recovery from chemotherapy effects before embarking upon surgery out of concern for wound healing.

We found that factors having the greatest correlation with a longer time to treatment initiation were higher volume facilities, increased income, and increased Charlson comorbidity index. Higher volume facilities may have longer wait times for consultations, resulting in delays to surgery or starting NAC. However, treatment at high volume centers has been shown to be associated with improved OS.[25](#cam42912-bib-0025){ref-type="ref"} It is unclear why higher income was associated with longer treatment times, but the most likely reason is that these patients have the financial means to obtain multiple opinions at different facilities, which lengthens the time from diagnosis to treatment initiation.[26](#cam42912-bib-0026){ref-type="ref"} Lastly, increased Charlson comorbidity index was also associated with a longer time to treatment initiation, presumably because these patients require more extensive evaluation and clearance before starting NAC or before proceeding to surgery.

We also found that patients treated at more than one facility, along with black and Hispanic patients had longer times to first treatment, radiation therapy and endocrine therapy, consistent with known disparities and the published medical literature. Stage for stage, black women have been found to have higher breast cancer mortality rates than white women,[27](#cam42912-bib-0027){ref-type="ref"}, [28](#cam42912-bib-0028){ref-type="ref"} which could be a result of either differences in access to care, or disparities in how care is delivered. Studies have also demonstrated that time from biopsy to treatment initiation is longer in black women[27](#cam42912-bib-0027){ref-type="ref"} and blacks and Hispanics have been found to have greater delays to surgery,[14](#cam42912-bib-0014){ref-type="ref"} all consistent with our findings here.

In contrast to income level, higher education level and having private insurance were associated with a shorter time to treatment initiation, radiotherapy, and endocrine therapy which might be explained, respectively, by knowledge of the disease and the imperative to be treated, and having access to more specialists to facilitate care. Being treated in an urban or rural setting as opposed to a metropolitan setting also resulted in shorter treatment times. Despite the smaller volume and potential shorter wait to see a physician, there are likely certain geographical areas which are lacking breast cancer specialists and have a longer delay. All of these findings indicate that, unfortunately, disparities remain in the neoadjuvant setting as well, and are not dependent on or related to treatment order.

Although this study utilizes a large prospectively collected validated dataset, it is limited by the NCDB's accuracy, which is dictated by how well the cases are coded into it. Additionally, like all datasets, the NCDB dataset is limited to specific variables, and unknown confounders could exist. Length of chemotherapy treatment, type of chemotherapy administered, and time to completion of endocrine therapy are not collected in this dataset, thus limiting our ability to assess how often truncation of those therapies occurs, and how timing is consequently affected. To overcome this, the time to initiation of endocrine therapy was used as a surrogate for the end of treatment. Our study\'s strengths include the very large size of the dataset utilized and its applicability to the national population at large, as well as its ability to discern precise intervals of treatment.

5. CONCLUSION {#cam42912-sec-0014}
=============

While there are clear indications for NAC in the treatment of breast cancer, NAC did not result in patients starting or completing treatment faster than those who received AC. Although one might consider its use if prolonged preoperative or postoperative delays are expected, quicker treatment initiation and completion should not be considered a routine benefit of NAC as vs primary surgery, and so this is not an indication to administer chemotherapy upfront.
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